CEL-SCI Future Growth

Future criteria checks 0/6

CEL-SCI is forecast to grow earnings and revenue by 22.5% and 150% per annum respectively while EPS is expected to grow by 30.6% per annum.

Key information

22.5%

Earnings growth rate

30.6%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	150.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	04 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:CVM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2026	13	-17	N/A	N/A	2
9/30/2025	N/A	-31	-32	-29	3
9/30/2024	N/A	-39	-39	-36	3
6/30/2024	N/A	-29	-19	-19	N/A
3/31/2024	N/A	-30	-20	-20	N/A
12/31/2023	N/A	-31	-23	-23	N/A
9/30/2023	N/A	-32	-23	-23	N/A
6/30/2023	N/A	-34	-23	-23	N/A
3/31/2023	N/A	-35	-23	-23	N/A
12/31/2022	N/A	-37	-19	-18	N/A
9/30/2022	N/A	-38	-19	-18	N/A
6/30/2022	N/A	-37	-19	-18	N/A
3/31/2022	N/A	-36	-21	-18	N/A
12/31/2021	N/A	-37	-26	-20	N/A
9/30/2021	N/A	-37	-28	-19	N/A
6/30/2021	0	-34	-27	-18	N/A
3/31/2021	0	-35	-25	-16	N/A
12/31/2020	1	-33	-21	-15	N/A
9/30/2020	1	-30	-18	-15	N/A
6/30/2020	1	-30	-17	-16	N/A
3/31/2020	1	-32	-17	-17	N/A
12/31/2019	0	-29	-17	-16	N/A
9/30/2019	0	-22	-17	-16	N/A
6/30/2019	1	-32	-17	-17	N/A
3/31/2019	1	-26	-15	-15	N/A
12/31/2018	1	-24	-15	-15	N/A
9/30/2018	0	-32	-13	-13	N/A
6/30/2018	0	-22	-13	-13	N/A
3/31/2018	0	-20	N/A	-13	N/A
12/31/2017	0	-24	N/A	-12	N/A
9/30/2017	N/A	-14	N/A	-14	N/A
6/30/2017	0	-10	N/A	-17	N/A
3/31/2017	0	-10	N/A	-20	N/A
12/31/2016	0	-10	N/A	-21	N/A
9/30/2016	0	-12	N/A	-23	N/A
6/30/2016	0	-20	N/A	-22	N/A
3/31/2016	0	-21	N/A	-22	N/A
12/31/2015	1	-25	N/A	-24	N/A
9/30/2015	1	-35	N/A	-24	N/A
6/30/2015	1	-32	N/A	-24	N/A
3/31/2015	0	-30	N/A	-24	N/A
12/31/2014	0	-31	N/A	-22	N/A
9/30/2014	0	-28	N/A	-23	N/A
6/30/2014	0	-23	N/A	-21	N/A
3/31/2014	0	-25	N/A	-18	N/A
12/31/2013	0	-12	N/A	-16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CVM is forecast to have no revenue next year.

High Growth Revenue: CVM is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CVM's Return on Equity is forecast to be high in 3 years time

CEL-SCI Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Recent updates

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

CEL-SCI Corporation Names Patricia B. Prichep as Chief Financial Officer

U.S. FDA and CEL-SCI Corporation Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence First Quarter 2025

CEL-SCI Corporation Reports New Data from Its Concluded Phase 3 Study of Multikine® (Leukocyte Interleukin, Injection)

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI Corporation A Pediatric Waiver, Bringing Multikine One Step Closer to Future Marketing Clearance

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $10.7737 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $10.845 million.

CEL-SCI Corporation Announces Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer

CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index

New major risk - Financial position

CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine

Less than half of directors are independent

No longer forecast to breakeven

New minor risk - Market cap size

CEL-SCI Corporation, Annual General Meeting, Apr 19, 2024

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $7.75 million.

CEL-SCI Corporation has completed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-SCI Corporation has filed a Follow-on Equity Offering in the amount of $4.98 million.

CEL-Sci Corporation Releases Video Detailing Recent Phase 3 Findings & Its Plans to Seek Immediate Regulatory Approvals

CEL-SCI Presents the Data for the First Time at the European Society for Medical Oncology Congress in Spain

New major risk - Share price stability

Cel-Sci Files Request with the Uk's Mhra Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

Cel-Sci Submits Scientific Advice Filing to European Medicines Agency (Ema) for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination with Checkpoint Inhibitors for Head & Neck Cancer

New minor risk - Market cap size

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer--New Patent to Be Filed

CEL-SCI Corporation Announces Latest Results from Its Pivotal Phase 3 Study of Multikine

No longer forecast to breakeven

Forecast breakeven date moved forward to 2023

Price target decreased by 23% to US$11.50

Consensus revenue estimates fall by 33%

Forecast breakeven date pushed back to 2024

Price target increased to US$15.00

Forecast breakeven date pushed back to 2024

CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results

CEL-SCI Corporation Appoints Gail Naughton to its Board of Directors

CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Growth Index

CEL-SCI Corporation, Annual General Meeting, Jun 13, 2022

Price target increased to US$15.00

Insufficient new directors

Chief Scientific Officer recently sold US$169k worth of stock

Price target decreased to US$12.00

Forecast breakeven pushed back to 2023

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Insider recently sold US$244k worth of stock

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

New 90-day high: US$26.54

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$0.82 loss per share

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as A Treatment for COVID-19 in Preclinical Studies

Insider notifies of intention to sell stock

Insider recently sold US$127k worth of stock

New 90-day low: US$11.56

New 90-day high: US$14.51

Analysts update estimates

Third quarter earnings released

New 90-day low - US$12.04

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies